Edding Genor Group Holdings Limited (6998) announced on 3 March 2026 that it entered into a supplemental agreement and a termination agreement with Nanopeptide (Qingdao) Biotechnology Ltd. These agreements adjust the in-licensing arrangements for certain siRNA assets.

According to the announcement, the territorial scope of the siRNA asset targeting ANGPTL3 is expanded from the originally agreed regions to a global scale. The group will obtain worldwide patent rights to this molecule and will jointly own the GalNAc platform technology with Nanopeptide. The group’s candidate, EDP167, which targets ANGPTL3, has completed its first subject dosing in a phase II clinical trial.

In addition, collaboration arrangements for two other pre-clinical siRNA assets have been terminated. These two assets remain at an early research stage, and the termination is not expected to create any material adverse impact on the group’s business or operations.